潜在的蛋白质血基生物标志物用于帕金森病的认知功能障碍:系统性审查和网络元分析
Youxue Tu1, Changmei Lu2,3,4, Bao Wu2,3
1Department of Rehabilitation, Fuzhou First General Hospital Affiliated with Fujian Medical University, Fuzhou, China.
Frontiers in aging neuroscience
|February 26, 2026
概括
这个网络元分析确定了帕金森病认知障碍的关键血液生物标志物. 囊素C,GDNF,NfL和IL-6在早期检测和监测PD患者的认知衰退方面表现有前途.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 神经退行性疾病 神经退行性疾病
背景情况:
- 帕金森病 (PD) 通常导致认知障碍 (PD-MCI) 和痴呆症 (PDD).
- 目前缺乏可靠的基于血液的生物标志物,用于早期检测和监测PD的认知衰退.
- 了解PD病理生理学对于开发有效的诊断工具至关重要.
研究的目的:
- 系统地评估和比较基于血液的蛋白质生物标志物,用于帕金森病的认知障碍.
- 确定潜在的生物标志物用于早期诊断和监测PD患者的认知衰退.
- 利用网络元分析 (NMA) 对现有证据进行全面评估.
主要方法:
- 在主要数据库 (PubMed,Embase,Web of Science,Scopus,Cochrane Library) 进行了系统的文献搜索,截至2025年1月.
- 包括的研究比较了PD患者的血液生物标志物水平认知障碍 (PD-CI) 与那些正常认知 (PD-NC).
- 使用随机效应模型进行频率网络元分析 (NMA),以估计标准化平均差异 (SMD) 和置信区间 (CI).
主要成果:
- 对47项研究的分析显示,与PD-NC相比,PD-CI中的几个血液蛋白质生物标志物的显著变化.
- 在PD-CI.中观察到高酸C (Cys C) (SMD=0.81) 和神经纤维光链 (NfL) (SMD=0.72) 的水平.
- 减少质细胞系衍生的神经营养因子 (GDNF) (SMD=-1.06) 和升高的INTERLEUKIN-6 (IL-6) (SMD=0.20) 也是PD-CI的重要发现.
结论:
- 囊素C (Cys C),GDNF,NfL和IL-6被确定为有希望的基于血液的生物标志物,用于检测帕金森病的认知障碍.
- 这些生物标志物反映了各种病理过程,为改善早期诊断和患者管理提供了潜力.
- 建议进行进一步的验证研究,以确认这些已识别的生物标志物的临床实用性.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.4K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.4K
相关概念视频
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation
43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
